NEW Oral Minoxidil For Hair Loss! The Truth About 'VDPHL01' - 4x More Effective?

VDPHL01: The “New Oral Minoxidil” in Development — What the Data Really Shows Are we on the brink of a brand-new, more effective version of oral minoxidil for male and female pattern hair loss? Early research on VDPHL01 (an extended-release, purpose-built oral minoxidil developed by DermaX/Veradermics in the USA) suggests it could be up to four times more effective than current oral or topical minoxidil options — and potentially better tolerated. As a hair-loss doctor who treats androgenetic alopecia daily (and someone who has personally navigated a 10-year AGA journey), I break down exactly what the science says so far, what’s promising, and what still needs to be proven. What you’ll learn in this video • What minoxidil actually does — and why only some people respond • Why traditional oral minoxidil peaks quickly and drops off within hours • How VDPHL01 works as an extended-release formulation • Why it may avoid cardiac peak-dose side effects seen with standard oral minoxidil • Phase 2 trial results: – +37.5 hairs/cm² at 2 months – +47.3 hairs/cm² at 4 months • Blinded comparison vs standard 5 mg oral minoxidil & 5% topical – ~82% “moderate improvement” with VDPHL01 – ~20% with existing treatments • Safety signals so far (including cardiac tolerability) • Limitations: tiny sample size, no peer-reviewed publication yet, short-duration studies, no female RCT data, BID dosing challenges • What the Phase 3 trials are designed to test • My clinical take — pros, cons, and what we still need to know before this becomes mainstream Why VDPHL01 matters For the first time, we may see a minoxidil formulation designed specifically for pattern hair loss, rather than a repurposed blood-pressure medication. Continuous drug exposure without hitting cardiac safety thresholds could change how we use minoxidil — if Phase 3 results confirm the early signals. Investment and trial momentum are strong, with over $220 million raised and multiple large RCTs (300+ men, 300+ women) now underway across the US. Earliest potential FDA approval (if successful): 2–3 years. My verdict (so far) Promising? Yes. Game-changing? Possibly. Ready to replace standard oral minoxidil? Too early to call. We need: • Larger, long-duration trials • Published, peer-reviewed data • Female-specific results • More safety insights (including hypertrichosis & TE rates) • Real-world compliance data with twice-daily dosing But if the efficacy and tolerability profile holds up, this may become only the third FDA-approved drug for pattern hair loss — a major milestone in the AGA space. Join the conversation Would you consider trying VDPHL01 once approved? Have you used oral or topical minoxidil before? Drop your thoughts and questions in the comments — I read every one. If you found this helpful, please like, subscribe, and stay tuned for next week’s video. Medical disclaimer: This email and video are for educational purposes only and do not constitute personalised medical advice. Always consult a qualified healthcare professional before starting, stopping, or adjusting any medication. Cheers, Dr Jonathan Hopkirk Hair-Loss Physician | Levels Of You™